Gepaglutide

Unassigned

New Medicines

Short bowel syndrome in adults

Information

New molecular entity
Zealand
Zealand

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Long-acting GLP-2 analogue
European prevalence of SBS is estimated to be 3.4 per 100,000 [1].
Short bowel syndrome in adults
Subcutaneous injection